Meeting
2022 ASCO Annual Meeting
Adherence to adjuvant endocrine therapy assessed by data from prescription renewals and medical records from tamoxifen in Swedish patients with cytochrome P450 2D6 (CYP2D6) genotyped early breast cancer.
Authors
Linda Thoren
Department of Clinical Science and Education at Sodersjukhuset, Karolinska Institutet. Department of Oncology, Sodersjukhuset, Stockholm, Sweden
Linda Thoren , Sara Margolin , Erik Eliasson , Jonas C. S. Bergh , Jonatan D. Lindh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 542)
DOI
10.1200/JCO.2022.40.16_suppl.542
Abstract #
542
Poster Bd #
314
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.
First Author: Stephanie L. Graff
Poster
2023 ASCO Annual Meeting
Influence of adherence to adjuvant endocrine therapy in early breast cancer: Results from a large German real-world claims data analysis.
First Author: Dominik Dannehl
Poster
2020 ASCO Virtual Scientific Program
Breast Cancer Index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial.
First Author: Gerrit-Jan Liefers
Poster
2013 ASCO Annual Meeting
Extended adjuvant tamoxifen for early breast cancer: A meta-analysis.
First Author: Eitan Amir